Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. (Q35001756)

5 August 2017

title

Homoharringtonine, omacetaxine mepesuccinate, and chronic myeloid leukemia circa 2009. (English)

1 reference

5 August 2017

main subject

chronic myeloid leukemia

0 references

1 reference

2

Hagop Kantarjian

1 reference

5 August 2017

3

Jorge Cortes

1 reference

5 August 2017

author name string

Alfonso Quintás-Cardama

series ordinal

1

1 reference

5 August 2017

publication date

1 December 2009

1 reference

5 August 2017

language of work or name

0 references

1 reference

5 August 2017

volume

115

1 reference

5 August 2017

issue

23

1 reference

5 August 2017

page(s)

5382-5393

1 reference

publication type of scholarly work

5 August 2017

review article

1 reference

Cytotoxicity and cell cycle specificity of homoharringtonine

cites work

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

Gene expression profiling in apoptotic k562 cells treated by homoharringtonine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

Homoharringtonine: history, current research, and future direction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Structures of harringtonine, isoharringtonine, and homoharringtonine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Antitumor alkaloids from Cephalotaxus harringtonia: structure and activity

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Tyrosine kinase activity and transformation potency of bcr-abl oncogene products.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Overriding imatinib resistance with a novel ABL kinase inhibitor

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Roots of clinical resistance to STI-571 cancer therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Inhibition of Translation in Eukaryotic Systems by Harringtonine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADP-ribose) polymerase (PARP).

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Effects of homoharringtonine alone and in combination with alpha interferon and cytosine arabinoside on 'in vitro' growth and induction of apoptosis in chronic myeloid leukemia and normal hematopoietic progenitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Drug responses of imatinib mesylate-resistant cells: synergism of imatinib with other chemotherapeutic drugs

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

In vitro cytotoxic effects of a tyrosine kinase inhibitor STI571 in combination with commonly used antileukemic agents

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

A sequential blockade strategy for the design of combination therapies to overcome oncogene addiction in chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Homoharringtonine: a phase I evaluation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Phase II study of homoharringtonine in patients with recurrent primary malignant central nervous system tumors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

A phase II trial of amonafide, caracemide, and homoharringtonine in the treatment of patients with advanced renal cell cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

A phase II trial of homoharringtonine and caracemide in the treatment of patients with advanced large bowel cancer

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Evaluation of homoharringtonine efficacy in the treatment of squamous cell carcinoma of the head and neck: a phase II Illinois Cancer Council Study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Homoharringtonine: an effective new drug for remission induction in refractory nonlymphoblastic leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Continuous infusion homoharringtonine (NSC 141633) in refractory acute nonlymphocytic leukemia. An ECOG pilot study

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Phase II study of low-dose continuous infusion homoharringtonine in refractory acute myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Results of triple therapy with interferon-alpha, cytarabine, and homoharringtonine, and the impact of adding imatinib to the treatment sequence in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in early chronic phase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Homoharringtonine and low-dose cytarabine in the management of late chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

A phase II study of continuous infusion homoharringtonine and cytarabine in newly diagnosed patients with chronic myeloid leukemia: CALGB study 19804.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Simultaneous homoharringtonine and interferon-alpha in the treatment of patients with chronic-phase chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Semisynthetic homoharringtonine induces apoptosis via inhibition of protein synthesis and triggers rapid myeloid cell leukemia-1 down-regulation in myeloid leukemia cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

MCL1, a gene expressed in programmed myeloid cell differentiation, has sequence similarity to BCL2

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Homoharringtonine induces apoptosis and growth arrest in human myeloma cells

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Anti-myeloma effect of homoharringtonine with concomitant targeting of the myeloma-promoting molecules, Mcl-1, XIAP, and beta-catenin

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Phase I/II study of subcutaneous homoharringtonine in patients with chronic myeloid leukemia who have failed prior therapy

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Phase I/II trial of adding semisynthetic homoharringtonine in chronic myeloid leukemia patients who have achieved partial or complete cytogenetic response on imatinib

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Structural mechanism for STI-571 inhibition of abelson tyrosine kinase

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Activation of tyrosine kinases by mutation of the gatekeeper threonine

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays.

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

BCR-ABL(T315I) transcript disappearance in an imatinib-resistant CML patient treated with homoharringtonine: a new therapeutic challenge?

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Flying under the radar: the new wave of BCR-ABL inhibitors

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Inhibitors of ABL and the ABL-T315I mutation

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Therapeutic options against BCR-ABL1 T315I-positive chronic myelogenous leukemia

1 reference

https://api.crossref.org/works/10.1002%2FCNCR.24601

7 January 2021

Identifiers

DOI

10.1002/CNCR.24601

1 reference

5 August 2017

1 reference